Efficacy of a Single Injection of CTM for Post-Operative CMC Arthritis

Launched by INDIANA HAND TO SHOULDER CENTER · Dec 6, 2023

Keywords

ClinConnect Summary

CTM Biomedical markets and distributes decellularized particulate human placental connective-tissue matrix products, intended solely for homologous use to supplement or replace damaged or inadequate connective-tissue. These are structural tissue allografts processed according to the criteria contained in 21CFR 1271.10(a) for regulation solely under section 361 of the Public Health Service Act. CTM Flow is decellularized particulate human placental connective-tissue matrix provided in a vial.

Postoperative pain after basilar thumb arthritis reconstruction is often quite significant. CTM flo...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Males or females age 18 or older
• • 2. Patients presenting for basilar thumb reconstruction surgery (any surgical technique)
• • 3. Patients who can consent to be a part of this study
• • 4. Patients who are able to return to the Indiana Hand to Shoulder Center or satellite location for follow up time points
• Exclusion Criteria:
• • 1. Additional procedures at the same time
• • 2. Patients with previous basilar thumb reconstruction on the operative side (revision surgery)
• • 3. Chronic narcotic use
• • 4. Women who are pregnancy or breastfeeding
• • 5. Non-English speaking